drugset / Trial / NCT00758225

Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)

NCT00758225

Phase 2 Completed 21 enrolled Santhera Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The scientific aim of the present extension study is to monitor long-term safety and tolerability of idebenone in patients with DMD. Furthermore, the long-term effect on respiratory, cardiac and motor functions, and skeletal muscle strength/function will be assessed.

Timeline

Start
2008-09
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Idebenone Small molecule 450 mg
Subject Idebenone Small molecule 900 mg